DTE Announces Appointment of Diego Areces as CEO
16.9.2021 08:00:00 EEST | Business Wire | Press release
The Board of DTE ehf. (DTE) (www.dte.ai), a leader in metals intelligence, is pleased to announce the appointment of Diego Areces as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915006176/en/
Diego Areces, CEO of DTE (Photo: Business Wire)
Diego Areces, who joined DTE in 2020 after a long tenure at Schneider Electric, succeeds Karl Matthiasson, one of the Company's two founders, who steps into the role of Chief Financial Officer.
The changes reflect DTE's increased commercial focus and reorganization to accelerate its market expansion, as it continues to innovate around its unique elemental analysis LP-LIBS™ technology, advances its real-time and predictive metals intelligence platform to the next level, and launches its forthcoming Series B financing round. Diego Areces' mission will be to lead DTE through its growth phase, while Karl Matthiasson, in his new role as CFO, will focus on solidifying DTE's financial foundation, expanding its global presence and leading the next funding round.
“I'm very pleased to take on the CEO role to continue building on the success of DTE’s technological accomplishments,” commented Mr. Areces. “Our disruptive technology is poised to transform the metals market and the team has developed solid relationships with strategic customers, which collectively form the launch pad of DTE's market expansion. Our metals intelligence platform enabled by our unique elemental analysis technology allows us to deliver beneficial financial and environmental business outcomes to our customers. We see ourselves as significant contributors to a carbon-neutral future and digital transformation towards Industry 4.0 for the industries we serve. I want to thank both Karl and Sveinn, the co-founders and prior CEOs, for their achievements and the support that they have provided to my appointment.”
“We’re delighted to announce Diego’s leadership and are convinced that he is the right person to drive DTE going forward,” commented DTE co-founder and CEO Karl Matthiasson. “We look forward to the next phase of the Company’s evolution and will continue to build a larger, stronger team to deliver the value that we can achieve through unlocking the future of metals.”
Richard MacKellar, Managing Partner at Chrysalix Ventures and Chairman of the Board of DTE, commented, “Chrysalix is excited and supportive of the nomination of Diego Areces as DTE's CEO. We welcome Diego to this new role in the Company as we continue to drive DTE's growth to fulfill its potential in leading a market of new and better, greener, safer, more efficient metals through technological innovation and value-added solutions. I would also like to thank and acknowledge Karl for his outstanding leadership up to this point, which continues with the challenge of leading DTE's financing and next funding rounds.”
Find out more about DTE's metals intelligence solutions at www.dte.ai.
About DTE ehf.
DTE, Unlocking the Future of Metals™, is the leading innovator in real-time intelligence from liquid metals, serving customers across the metals production and manufacturing value chain through maximizing value, sustainability, safety, and efficiency for all stakeholders.
Our purpose is advancing human progress with greener, safer, more efficient, and more valuable metals, contributing to the 1.5-degree challenge while driving its digital transformation towards Industry 4.0 with the next generation of IIoT analysis technology. DTE provides tangible financial and environmental business outcomes from the plant floor to the business levels through valuable intelligence and predictive insights from liquid metals.
IREAS, DTE's unique, connected, real-time intelligence from liquid metals solution seamless integrated IT and OT, combining chemical composition analysis from molten metals based on Liquid-Phase Laser-Induced Breakdown Spectroscopy (LP-LIBS™) with an artificial intelligence-based analytics platform and digital metals intelligence services.
For more information, please visit www.dte.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915006176/en/
Contact information
DTE ehf.
Diego Areces, CEO
diego.areces@dte.ai
(+354) 698 0173
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom